KalVista Pharmaceuticals Inc [NASDAQ: KALV] stock went on an upward path that rose over 25.71% on Monday, amounting to a one-week price increase of more than 31.99%.
Over the last 12 months, KALV stock rose by 77.80%. The one-year KalVista Pharmaceuticals Inc stock forecast points to a potential upside of 48.83. The average equity rating for KALV stock is currently 1.00, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $748.71 million, with 49.49 million shares outstanding and 38.49 million shares in the current float. Compared to the average trading volume of 752.21K shares, KALV stock reached a trading volume of 11282321 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on KalVista Pharmaceuticals Inc [KALV]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for KALV shares is $29.43 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on KALV stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
JMP Securities have made an estimate for KalVista Pharmaceuticals Inc shares, keeping their opinion on the stock as Mkt Outperform, with their previous recommendation back on January 31, 2025. While these analysts kept the previous recommendation, TD Cowen raised their target price to Buy. The new note on the price target was released on January 07, 2025, representing the official price target for KalVista Pharmaceuticals Inc stock. Previously, the target price had yet another raise to $22, while BofA Securities analysts kept a Buy rating on KALV stock.
The Price to Book ratio for the last quarter was 5.14, with the Price to Cash per share for the same quarter was set at 5.09.
KALV Stock Performance Analysis:
KalVista Pharmaceuticals Inc [KALV] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 31.99. With this latest performance, KALV shares gained by 11.23% in over the last four-week period, additionally plugging by 77.80% over the last 6 months – not to mention a rise of 77.80% in the past year of trading.
Insight into KalVista Pharmaceuticals Inc Fundamentals:
Return on Equity for this stock declined to -90.20%, with Return on Assets sitting at -90.20%.
KALV Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for KALV. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for KalVista Pharmaceuticals Inc go to 24.62%.
KalVista Pharmaceuticals Inc [KALV] Institutonal Ownership Details
The top three institutional holders of KALV stocks are: VR ADVISER, LLC with ownership of 6.25 million shares, which is approximately 13.5179%. TANG CAPITAL MANAGEMENT LLC, holding 4.22 million shares of the stock with an approximate value of $$49.7 million in KALV stocks shares; and TANG CAPITAL MANAGEMENT LLC, currently with $$49.38 million in KALV stock with ownership which is approximately 9.0671%.
